Parameter
| Biomarker | ENO1 | Full name | Enolase 1 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prediction of TKI treatment response, therapeutic targets. |
| Disease | Chronic Myeloid Leukemia(CML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Cell line/patient sample (metabolomics analysis, Western blot) | ||
| Pathobiological Mechanisms | Drug-resistant cells exhibit greater dependence on their mediated glycolysis, and downregulation can induce autophagic degradation and ferroptosis of GPX4. | ||||
| Clinical Availability Status | Research validation: exhibits negative correlation with TMEM164, and the combination of inhibitors enhances TKI sensitivity. | ||||
| Notes and Dynamics | Regulating ferroptosis through the AMPK/mTOR pathway provides a basis for combination therapy. | ||||